马来酸丙氯拉嗪市场（依适应症、剂型、通路、最终用户及地区划分）

预计 2025 年马来酸丙氯拉嗪市场规模为 16.1 亿美元，到 2032 年将达到 20.3 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 3.4%。

马来酸丙氯拉嗪用于治疗严重的噁心和呕吐，并改善思觉失调症和焦虑症患者的情绪、思维和行为。它属于吩噻嗪类药物。此药物的作用机转是影响脑部化学反应。因此，身体可能会产生更多的多巴胺，这是一种有助于运动和愉悦感的神经传导物质。它也可能掩盖导致噁心和呕吐的更严重的疾病，例如药物过量摄取或中毒、脑肿瘤、脑损伤和雷氏症候群。吩噻嗪类抗精神病药物之一是马来酸丙氯拉嗪。

市场动态：

预测期内，呕吐和噁心频率的增加将继续推动全球马来酸丙氯拉嗪市场的成长。由于慢性病发病率上升和人口老化，需要止吐治疗的人数正在增加。此外，患者意识的提高也将持续推动全球马来酸丙氯拉嗪市场的成长。患者正在寻找合适的替代疗法，并更积极地与医疗保健提供者讨论相关问题。联合治疗的出现可能会在预测期内为全球马来酸丙氯拉嗪市场创造新的机会。对含有马来酸丙氯拉嗪的复方药物进行分析，具有市场成长的潜力。

预计在预测期内，安全问题和负面副作用将阻碍全球马来酸丙氯拉嗪市场的成长。

本报告的主要特点

• 本报告对全球马来酸丙氯拉嗪市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。
• 它还强调了每个细分市场的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 全球马来酸丙氯拉嗪市场的主要企业根据以下参数列出，例如公司概况、产品系列、主要亮点、财务表现和策略。
• 透过本报告的见解，负责人和企业经营团队可以就未来的产品发布、合作伙伴关係、市场扩张和行销策略做出明智的决策。
• 「全球马来酸丙氯拉嗪市场」报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球马来酸丙氯拉嗪市场的各种策略矩阵轻鬆做出决策。

目录

第一章 分析目标与前提条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特五力分析
• 企业合併（M&A）场景

4. 马来酸丙氯拉嗪市场：COVID-19感染疾病的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 马来酸丙氯拉嗪市场（依适应症划分） (2020-2032)

• 抑制噁心和呕吐
• 头晕
• 晕动病

6. 马来酸丙氯拉嗪市场（按剂型划分） (2020-2032)

• 口服锭剂
• 直肠栓剂
• 注射

7. 马来酸丙氯拉嗪市场依通路划分（2020-2032 年）

• 医院药房
• 零售药局
• 网路药局

8. 马来酸丙氯拉嗪市场（按地区） （2020-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 中东
  • GCC
  • 以色列
  • 其他中东地区
• 非洲
• 北非
• 南非
• 中部非洲

第九章 竞争态势

• Sandoz Inc
• Mylan Pharmaceuticals Inc.
• ABneal Pharmaceuticals LLC
• Glenmark Pharmaceuticals Inc
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Aurobindo Pharma Ltd
• Aspen Pharma Trading Limited
• FAGRON
• Sanofi
• GlaxoSmithKline
• Hikma Pharmaceuticals

第 10 章 章节

• 分析方法
• 关于出版商

Prochlorperazine Maleate Market is estimated to be valued at USD 1.61 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.4% from 2025 to 2032.

Prochlorperazine maleate is utilized for treating severe nausea and vomiting as well as to help people with schizophrenia or anxiety have better moods, thinking, and conduct. It is a member of the phenothiazine class of drugs. The way this drug affects brain chemistry is how it functions. Dopamine, a neurotransmitter that aids in movement and pleasure, might then be produced in greater amounts by the body as a result. It can also mask more serious illnesses that produce nausea and vomiting, such as drug overdose or poisoning, brain tumors, brain injuries, or Reye's syndrome. A medicine from the phenothiazine class of antipsychotics is called prochlorperazine maleate.

Market Dynamics:

The increasing frequency of vomiting and nausea will continue to fuel growth of the global prochlorperazine maleate market over the forecast period. The number of people requiring antiemetic therapy is rising as a result of rising chronic disease prevalence and an aging population. Growing patient awareness will also continue to fuel growth of the global prochlorperazine maleate market over the forecast period. Patients are more active in seeking out the right therapy alternatives and talking about their issues with medical providers. The creation of combination therapies will create new opportunities for the global prochlorperazine maleate market over the forecast period. There is potential for market growth in the investigation of combination medicines containing prochlorperazine maleate.

Safety issues and negative side effects are expected to hamper growth of the global prochlorperazine maleate market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global prochlorperazine maleate market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global prochlorperazine maleate market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc, Pfizer Inc., Novartis AG, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global prochlorperazine maleate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prochlorperazine maleate market

Global Prochlorperazine Maleate Market Detailed Segmentation:

• By Indication:
  • Nausea and Vomiting Management
  • Vertigo
  • Mental Health Disorders (e.g., Schizophrenia)
• By Dosage Form:
  • Oral Tablets
  • Rectal Suppositories
  • Injectable Formulations
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End User:
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
• By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profile:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Pu rview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Prochlorperazine Maleate, By Indication
  • Market Prochlorperazine Maleate, By Dosage Form
  • Market Prochlorperazine Maleate, By Distribution Channel
  • Market Prochlorperazine Maleate, By End User
  • Market Prochlorperazine Maleate, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Prochlorperazine Maleate Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Prochlorperazine Maleate Market , By Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Nausea and Vomiting Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vertigo
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Motion Sickness
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Prochlorperazine Maleate Market , By Dosage Form, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Rectal Suppositories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Injectable Formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Prochlorperazine Maleate Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Prochlorperazine Maleate Market , By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2020-2032,(US$ Bn)
• North Africa
• South Africa
• Central Africa

9. Competitive Landscape

• Sandoz Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• ABneal Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Aurobindo Pharma Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Aspen Pharma Trading Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• FAGRON
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us